Literature DB >> 19540560

Lower- and higher-grade subtypes of diffuse gastric cancer.

Anna Maria Chiaravalli1, Catherine Klersy, Francesca Tava, Rachele Manca, Roberto Fiocca, Carlo Capella, Enrico Solcia.   

Abstract

Diffuse gastric cancer, characterized by poorly cohesive, diffusely infiltrating cells with no or little gland formation, is known to show several morphologic variants, but their prognostic value, if any, is poorly documented. In this article, 119 cases of invasive (T1b to T4) diffuse gastric cancer, which had undergone potentially curative surgery and were followed postoperatively for a median time of more than 10 years, were investigated for histologic or histochemical patterns possibly predictive of survival. Among 5 histologic groups identified, a low-grade subtype (17 cases) with prominent desmoplasia closely surrounding individual tumor cells (tumor embedding desmoplasia) and no or scarce angio-lympho-neuroinvasion showed stage-independent improved survival compared with 36 non-low-grade desmoplastic, 24 signet ring, and 28 diffuse cancers not otherwise specified. Fourteen cases with anaplastic cells showed clinicopathologic patterns and outcome of highly malignant neoplasms. None of the tumor cell differentiation markers (including 6 mucins and 3 proteases) nor proliferative index or p53 protein expression had independent predictive power, although MUC1 was significantly less expressed in low-grade desmoplastic cases. Cox survival analysis showed the significantly better prognosis of 17 low-grade desmoplastic and worse prognosis of 14 anaplastic cancers compared with the remaining 88 cases. In conclusion, a low-grade desmoplastic and a high-grade anaplastic subtype should be separated histologically from the bulk of diffuse gastric cancers owing to their distinctive histologic, clinicopathologic, and prognostic aspects.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19540560     DOI: 10.1016/j.humpath.2009.04.004

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  6 in total

1.  Histotype-based prognostic classification of gastric cancer.

Authors:  Anna Maria Chiaravalli; Catherine Klersy; Alessandro Vanoli; Andrea Ferretti; Carlo Capella; Enrico Solcia
Journal:  World J Gastroenterol       Date:  2012-03-07       Impact factor: 5.742

2.  Survival following operative management of gastric linitis plastica compared with non-operative management.

Authors:  R J Thompson; L Ranaghan; R Kennedy; Wdb Clements; P D Carey; J A Kennedy
Journal:  Ann R Coll Surg Engl       Date:  2016-11-04       Impact factor: 1.891

3.  The contribution of cell phenotype to the behavior of gastric cancer.

Authors:  Enrico Solcia; Catherine Klersy; Alessandro Vanoli; Federica Grillo; Rachele Manca; Francesca Tava; Ombretta Luinetti; Roberto Fiocca
Journal:  Gastric Cancer       Date:  2013-01-18       Impact factor: 7.370

4.  A combined histologic and molecular approach identifies three groups of gastric cancer with different prognosis.

Authors:  Enrico Solcia; Catherine Klersy; Luca Mastracci; Paola Alberizzi; Maria Elena Candusso; Marta Diegoli; Francesca Tava; Roberta Riboni; Rachele Manca; Ombretta Luinetti
Journal:  Virchows Arch       Date:  2009-08-12       Impact factor: 4.064

5.  Reproducibility of histological subtyping of malignant pleural mesothelioma.

Authors:  Luka Brčić; Marko Jakopović; Iva Brčić; Vlasta Klarić; Milan Milošević; Ana Sepac; Miroslav Samaržija; Sven Seiwerth
Journal:  Virchows Arch       Date:  2014-10-10       Impact factor: 4.064

Review 6.  Mucin expression in gastric- and gastro-oesophageal signet-ring cell cancer: results from a comprehensive literature review and a large cohort study of Caucasian and Asian gastric cancer.

Authors:  K G P Kerckhoffs; D H W Liu; L Saragoni; R S van der Post; R Langer; M Bencivenga; M Iglesias; G Gallo; L C Hewitt; G E Fazzi; A M Vos; F Renaud; T Yoshikawa; T Oshima; A Tomezzoli; G de Manzoni; T Arai; R Kushima; F Carneiro; H I Grabsch
Journal:  Gastric Cancer       Date:  2020-06-02       Impact factor: 7.370

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.